Highwise Health
U.S.

FDA Agreed on Phase 3 Protocol for Sarcoidosis Drug

The trial will evaluate efzofitimod in hundreds of patients to measure its impact on lung function.

Updated on Sept. 24, 2026 in Asthma

Isometric editorial illustration of a sterile intravenous drip bag on a simple metal stand, representing clinical trial procedures.
The FDA has reached a formal agreement with aTyr Pharma for the Phase 3 clinical trial protocol of efzofitimod for sarcoidosis patients. AI Illustration. Upload story photo >

Live Poll

Do you trust companies undergoing significant workforce reductions to successfully reach their long-term project goals?

aTyr Pharma has secured a formal agreement with the FDA to proceed with a Phase 3 study of the drug efzofitimod for patients with sarcoidosis. The trial is scheduled to begin its initial activities in the United States and Europe in the fourth quarter of 2026.

Why it matters

This agreement sets the stage for a late-stage clinical evaluation of a potential new treatment option for lung-related sarcoidosis. The company is advancing this research as it continues to manage its internal capital and operational resources.

The upcoming Phase 3 randomized trial will enroll up to 372 patients over a 54-week study duration. Researchers will evaluate the drug's efficacy through primary endpoint tracking of forced vital capacity changes and secondary lung health assessments at week 48.

The players

aTyr Pharma

A biotechnology company focused on the development of therapeutics for lung diseases and inflammation.

FDA

The federal agency responsible for overseeing the safety and efficacy of medical products in the United States.

The details

The study will divide participants into two parallel cohorts to receive either a placebo or 5.0 mg/kg of efzofitimod intravenously every three weeks. Over the course of the 54-week study, each participant will receive 17 doses of the treatment or placebo. During this period, all patients will continue their existing background treatments, including oral corticosteroids and immunosuppressants, to maintain consistent care standards.

Timeline

  1. June 30: The company reported cash and cash equivalents of $58.9 million.

  2. August: The company reduced its workforce by 60 percent.

  3. September 24, 2026: The FDA agreement was confirmed.

  4. Q4 2026: Planned initiation of study-related activities.

  5. Late 2028: Projected end of current operational funding.

Health Landscape

The FDA's formal Phase 3 protocol agreement process ensures that study endpoints are sufficiently rigorous to support potential future drug approval. This development marks a critical milestone in formalizing the path toward evaluating efzofitimod for patients with lung-related sarcoidosis.

This study is in the development phase and is not yet available for clinical use. If you are managing sarcoidosis, discuss the landscape of emerging clinical research with your physician to stay informed about potential future treatment options.

The takeaway

This news indicates a formal path for testing a new therapeutic agent in a large patient population. Patients interested in how new medications reach the clinic should monitor trial progress on official government registries like ClinicalTrials.gov.

Further reading

For more information on current treatment trends for chronic respiratory conditions, visit the Asthma section.

Live Poll

Do you trust companies undergoing significant workforce reductions to successfully reach their long-term project goals?